Lung cancer is the most fatal cancer in the world, killing about 1.3 million people each year.The staging evaluation of this cancer is an important basis for determining the extent of cancer spread and the subsequent treatment choices and prognosis.As the disease staging becomes later, it is usually found that treatment is more difficult and the prognosis becomes worse.In the staging of lung cancer, the TNM system is a key assessment tool that classifies the size of the primary tumor, the lymph node involvement, and the distant metastasis.
When initially assessing the stage of non-small cell lung cancer, the tumor can be divided into corresponding stages according to TNM classification, from hidden cancer to stage IV, which provides a basis for choosing treatment methods and predicting the patient's prognosis.
The evaluation of staging can be mainly divided into non-invasive and invasive categories.Non-invasive techniques often involve medical imaging of the lungs, such as computed tomography (CT) and positron emission tomography (PET).Invasive technologies include biopsy and surgery, which can provide more information to confirm the presence of cancer cells and the type and grading of cancer.
Clinical staging is usually performed before the surgery is determined and evaluated based on the results of an imaging study and the results of a biopsy.On the other hand, pathological staging is evaluated during or after the operation based on the surgical results and previous clinical results, and includes sectional analysis of thoracic lymph nodes.The correctness of this process is crucial to developing an effective treatment plan, as different lung cancer types and stages will lead to different treatment options.
The main types of lung cancer include non-small cell lung cancer and small cell lung cancer. These two are significantly different in histology and have different treatment methods; non-small cell lung cancer is mainly surgery, while small cell lung cancer is even more common Chemotherapy and radiotherapy are often selected.
According to data from the World Health Organization (WHO), lung cancer caused about 10 million deaths in 2020, and long-term smoking is the main cause of lung cancer.Among the deaths of lung cancer in the United States, 80%-90% are smokers, while about 15% of non-smokers may suffer from lung cancer due to genetic factors, radon, asbestos and air pollution.
Lung cancer usually starts somewhere in the lungs and follows a predictable way of spreading.If lung cancer spreads, it first reaches nearby lymph nodes, and then may further spread to further distant lymph nodes and other organs, such as the liver or adrenal glands, and eventually evolve into a stage 4 advanced disease.
The purpose of the lung cancer staging process is to determine the scope and location of cancer in the body.Access to this information is crucial before surgery, as different proportions of cancer correspond to different treatment options, which is a complex decision-making process for doctors.
The lung cancer biopsy is performed not only to confirm whether the abnormalities seen on chest X-rays or CT scans are indeed lung cancer, but also to determine the histological type and stage of the cancer.
The TNM staging system consists of three main parts: T (tumor), N (lymph node) and M (metastasis).Each section is broken down into different types according to its characteristics to help doctors develop appropriate treatment plans.
CT scan and PET scan are the main techniques for non-invasive staging.CT scans help identify lumps or enlarged lymph nodes in the lungs, while PET scans reveal increased metabolism in the structure, which is usually caused by rapidly growing cancer cells.PET/CT is considered a major advance in lung cancer staging.
As technology advances, the accuracy of staging has also improved, which allows doctors to more accurately judge the patient's condition and formulate treatment plans.However, continuous clinical examination and multidisciplinary group collaboration are crucial for optimal treatment outcomes.
Today, staging methods for lung cancer are not limited to traditional CT and MRI examinations, but also include new technologies such as endoscopic ultrasound to accurately evaluate the status of lymph nodes and surrounding tissues.
The staging process of lung cancer continues to change with advances in medical research and technology. Does this cause us to start thinking about how to use this new knowledge to improve the future of patients?